Research graph

References

References from Correction: Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure. Local targets link to admitted publications; unresolved targets remain external evidence.